{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:13:57Z","timestamp":1761902037543,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.msard.2023.104699","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T02:21:43Z","timestamp":1680488503000},"page":"104699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-0320","authenticated-orcid":false,"given":"Maria-Elizabeth","family":"Baeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luanne M","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos R.","family":"Camara-Lemarroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2023.104699_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40120-017-0080-x","article-title":"Effectiveness and safety of dimethyl fumarate treatment in relapsing multiple sclerosis patients: real-world evidence","volume":"6","author":"Alroughani","year":"2017","journal-title":"Neurol. Ther."},{"issue":"11","key":"10.1016\/j.msard.2023.104699_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112361","article-title":"Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects","volume":"9","author":"Azab","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2023.104699_bib0037","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2017.10.009","article-title":"The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis","volume":"18","author":"Bisgaard","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2023.104699_bib0026","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104699_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103887","article-title":"Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis","volume":"63","author":"Borrelli","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.104699_bib0027","first-page":"73","article-title":"Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis","volume":"45","author":"Boullosa-Lale","year":"2020","journal-title":"Farm Hosp."},{"key":"10.1016\/j.msard.2023.104699_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419843450","article-title":"Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age","volume":"12","author":"Briner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.104699_bib0032","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jcmg.2015.05.003","article-title":"Eosinophil-mediated cardiac injury possibly due to dimethyl fumarate","volume":"9","author":"Brown","year":"2016","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"2","key":"10.1016\/j.msard.2023.104699_bib0024","article-title":"Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis","volume":"6","author":"Buckle","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2023.104699_bib0006","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41467-019-11139-3","article-title":"Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes","volume":"10","author":"Carlstr\u00f6m","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2023.104699_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107710","article-title":"Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature","volume":"219","author":"Dello Russo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.msard.2023.104699_bib0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.26328","article-title":"Immunological predictors of dimethyl fumarate-induced lymphopenia","volume":"91","author":"Diebold","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104699_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2022.2147055","article-title":"Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis","volume":"14","author":"Diebold","year":"2022","journal-title":"Gut Microbes"},{"key":"10.1016\/j.msard.2023.104699_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102781","article-title":"Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment","volume":"49","author":"Garbo","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104699_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.104699_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228617","article-title":"Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients","volume":"15","author":"Goldman","year":"2020","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.msard.2023.104699_bib0001","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/03007995.2018.1458023","article-title":"Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment","volume":"34","author":"Grand'Maison","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.msard.2023.104699_bib0038","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12883-019-1245-2","article-title":"The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis","volume":"19","author":"Hemond","year":"2019","journal-title":"BMC Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.104699_bib0030","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1007\/s00415-020-09895-0","article-title":"Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent","volume":"267","author":"Koch","year":"2020","journal-title":"J. Neurol."},{"issue":"26","key":"10.1016\/j.msard.2023.104699_bib0012","doi-asserted-by":"crossref","first-page":"e11138","DOI":"10.1097\/MD.0000000000011138","article-title":"Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.msard.2023.104699_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102566","article-title":"Safety of dimethyl fumarate for multiple sclerosis: a systematic review and meta-analysis","volume":"46","author":"Liang","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104699_bib0019","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.104699_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10412-0","article-title":"Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis","author":"Lucchini","year":"2021","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.104699_bib0013","article-title":"Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort","author":"Manni","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2023.104699_bib0018","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study","volume":"32","author":"Mirabella","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2023.104699_bib0029","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","article-title":"Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients","volume":"8","author":"Montes Diaz","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2023.104699_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104699_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.19899","article-title":"Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of psoriasis patients that are linked with skin improvement","author":"Morrison","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.msard.2023.104699_bib0031","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1365-2133.1998.02124.x","article-title":"Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study","volume":"138","author":"Mrowietz","year":"1998","journal-title":"Br. J. Dermatol."},{"year":"2009","series-title":"Common Terminology Criteria for Adverse Events v4.0, NCI, NIH, DHHS","key":"10.1016\/j.msard.2023.104699_bib0008"},{"issue":"3","key":"10.1016\/j.msard.2023.104699_bib0034","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.iac.2007.07.008","article-title":"Evaluation and differential diagnosis of marked, persistent eosinophilia","volume":"27","author":"Nutman","year":"2007","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.msard.2023.104699_bib0014","doi-asserted-by":"crossref","unstructured":"Paul A., Comabella M., Gandhi R. Biomarkers in multiple sclerosis. Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a029058. doi: 10.1101\/cshperspect.a029058.","DOI":"10.1101\/cshperspect.a029058"},{"issue":"9","key":"10.1016\/j.msard.2023.104699_bib0033","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1212\/WNL.0000000000003045","article-title":"Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate","volume":"87","author":"Purchiaroni","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104699_bib0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2023.104699_bib0011","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41598-020-79431-7","article-title":"Neutrophil-to-lymphocyte ratio and mortality in the United States general population","volume":"11","author":"Song","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.msard.2023.104699_bib0036","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2023.104699_bib0007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/09546634.2019.1605135","article-title":"Association of lymphopenia and eosinophilia with dimethylfumarate treatment efficacy and tolerability in psoriasis: a retrospective study","volume":"31","author":"van Hezik","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.msard.2023.104699_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00421-021-04668-7","article-title":"Transferring clinically established immune inflammation markers into exercise physiology: focus on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index","author":"Walzik","year":"2021","journal-title":"Eur. J. Appl. Physiol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:45Z","timestamp":1761901545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":38,"alternative-id":["S2211034823002031"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104699","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104699"}}